Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06075524 · ClinicalTrials.gov registry record
Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types
A clinical trial of Metastatic Malignant Solid Neoplasm and Metastatic Melanoma, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- 500
- Enrollment target
- 1
- Study location
NCT06075524 is a study of Metastatic Malignant Solid Neoplasm and Metastatic Melanoma that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 500 participants, above the 201-participant average among 92 other Metastatic Malignant Solid Neoplasm trials with a reported enrollment target (149% higher). The trial reports 1 study location across 1 state.
The verdict
NCT06075524, a study of Metastatic Malignant Solid Neoplasm and Metastatic Melanoma, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 1
- Study location
Study Summary
This study explores the role of T cells in monitoring disease status and response during anti-PD-1/PD-L1 treatment in patients with melanoma, lung and other cancer types. Measuring levels of specific targets such as Bim and soluble PD-L1 during therapy may help track treatment resistance and clinical outcomes. This information may also help researchers determine why some people with melanoma, lung and other cancer types respond to PD-1/PD-L1 treatment and others do not.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- OTHER Electronic Health Record Review
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2015-06-15 |
| Est. Completion | 2026-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06075524
The ClinicalTrials.gov registry entry for NCT06075524 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 201-participant average among 92 other Metastatic Malignant Solid Neoplasm trials with a reported enrollment target (149% higher). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Metastatic Malignant Solid Neoplasm appearing as the primary indexed condition, and to 2 interventions - of which Biospecimen Collection is the first listed.
NCT06075524 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT06075524 about?
NCT06075524 is a clinical study titled "Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types". This study explores the role of T cells in monitoring disease status and response during anti-PD-1/PD-L1 treatment in patients with melanoma, lung and other cancer types. Measuring levels of specific targets such as Bim and soluble PD-L1 during therapy may help track treatment resistance and clinica...
What is the current status of trial NCT06075524?
This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2015-06-15. Estimated completion is 2026-12-31.
What conditions does trial NCT06075524 study?
This clinical trial studies the following conditions: Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Stage IV Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8.
What interventions are being tested in trial NCT06075524?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Electronic Health Record Review (OTHER).
Who is sponsoring clinical trial NCT06075524?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06075524 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Malignant Solid Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
RECRUITING · Phase 1
-
Spatiotemporal Stereotactic Body Radiation Therapy for the Treatment of Patients With Polymetastatic Solid Tumors
RECRUITING · NA
-
Collection and Storage of Tissue and Blood Samples From Patients With Cancer
RECRUITING
-
Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors
RECRUITING · Phase 1
-
Parenting Support Intervention for Families Coping With Metastatic or Locally Recurrent Solid Tumor Diagnosis
RECRUITING · NA
-
Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.